LIPOCINE REPORTS POSITIVE CLINICAL RESULTS FOR NOVEL ONCE-A-DAY ORAL TESTOSTERONE

LIPOCINE ORAL TESTOSTERONE REPLACEMENT PRODUCT CLEARED BY FDA FOR PHASE III STUDY

LIPOCINE CHAIRMAN AWARDED PRESTIGIOUS "ORDER OF THE RISING SUN" BY THE JAPANESE GOVERNMENT

LIPOCINE INC. STRENGTHENS ITS ORAL TESTOSTERONE IP PORTFOLIO

LIPOCINE AWARDED $978,000 IN GRANTS FOR QUALIFYING THERAPEUTIC DISCOVERY PROJECTS